Clinical Trial: Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583589) titled 'Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)' on Sept. 04, 2025.

Brief Summary: Nintedanib combined with or without Dextromethorphan for the treatment of IPF, with FVC as the primary efficacy endpoint to evaluate its effectivenes.

Study Start Date: May 12

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: DRUG: Nintedanib,Dextromethorphan

Dosage of Nitedanib is 150mg/100mg each time, twice a day, once in the morning and once in the evening, It is recommended to take it with meals. The dosage of Dextromethorphan sustained-release tablets is...